Conversion from azathioprine/prednisone to azathioprine/cyclosporin promotes catch‐up growth in pediatric renal allograft recipients

Authors:

Abstract
Fifteen pediatric renal allografts recipients under azathioprine (AZA) 2–2.5 mg/kg/day and prednisone (PRED) (5.4 $pM 2.9 mg/m2/d) had their immunosuppression switched to AZA/cyclosporin (CSA) to evaluate benefits on linear growth. Before and after conversion, growth hormone (GH) nocturnal spontaneous secretion (GHss) and somatomedin C basal levels were measured. GH stimulation test (GHst) and SMc generation (SMcG) were also measured but only during the AZA/PRED period. GHst was normal in all children. GH levels increased from 2.6 $pM 2.5 to 20.9 $pM 7.9 ng/ml (p $lt 0.005) after hypoglycemia. The SMc levels, during SMcG, increased from 1.12 $pM 0.41 to 3.73 $pM 1.48 (p $lt 0.005), which is considered a normal response in our laboratory. GH nocturnal secretion inversely correlated to PRED dosage (r = 0.6, p $lt 0.02). GHss increased after PRED withdrawal in the 6 children on PRED 7.0 $pM 3.0 mg/m2/d. On the other hand, bSMc levels did not increase after conversion. After conversion, growth rate increased from 0.34 $pM 0.21 to 0.68 $pM 0.20 cm/month (p $lt 0.0004). The group showed a catch‐up growth from – 3.7 $pM 1.6 to – 2.7 $pM 1.7 standard deviation scores (p $lt 0.0001) after 1 year of follow‐up. Serum creatinine increased slightly from 0.9 $pM 0.2 to 1.0 $pM 0.4 mg/dl. AZA/CSA represents a good alternative for the pediatric recipient of a renal allograft since it is safe to both the child and the graft. This immunosuppressive regimen allows linear growth to occur.

This publication has 13 references indexed in Scilit: